
|Videos|May 27, 2022
ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings
Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
2
Understanding The Training, Credentialing Landscapes for End-of-Life Doulas
3
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5



























































